BMO Capital Reiterates Outperform Rating on AstraZeneca (AZN)
Tweet Send to a Friend
BMO Capital analyst Etzer Darout reiterated an Outperform rating and $82.00 price target on AstraZeneca (NASDAQ: AZN).The analyst commented, "AZN ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
